Treatment of Patients With Major Depressive Disorder With MK0869 (0869-061)

Merck Sharp & Dohme (MSD)

Status and phase: Completed; Phase 3

Conditions: Major Depressive Disorder

Treatments: Drug: Comparator: placebo; Drug: MK0869, aprepitant

Study type: Interventional

Funder types: Industry

Identifiers

NCT00035295

2006_404

0869-061

Details and patient eligibility

About

A clinical study to determine the efficacy and safety of an Treatment of MK0869

in the treatment of depression.

Full description

The duration of treatment is 8 weeks.

Enrollment: 584 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Patients with Major Depressive Disorder

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind